Charite Clinical Research Organisation

Berlin, Germany

Charite Clinical Research Organisation

Berlin, Germany
SEARCH FILTERS
Time filter
Source Type

Winterer G.,University of Cologne | Winterer G.,Jülich Research Center | Winterer G.,PharmaImage Biomarker Solutions GmbH | Winterer G.,Ludwig Maximilians University of Munich | And 18 more authors.
Neuropharmacology | Year: 2013

In this multicenter, double-blind, placebo-controlled, randomized, four way cross-over proof-of-mechanism study, we tested the effect of the positive allosteric α7 nicotinic acetylcholine receptor (nAChR) modulator JNJ-39393406 in a key translational assay (sensory P50 gating) in 39 regularly smoking male patients with schizophrenia. All patients were clinically stable and JNJ-39393406 was administered as an adjunct treatment to antipsychotics. No indication was found that JNJ-39393406 has the potential to reverse basic deficits of information processing in schizophrenia (sensory P50 gating) or has a significant effect on other tested electrophysiological markers (MMN, P300 and quantitative resting EEG). Sensitivity analyses including severity of disease, baseline P50 gating, medication and gene variants of the CHRNA7 gene did not reveal any subgroups with consistent significant effects. It is discussed that potential positive effects in subgroups not present or not large enough in the current study or upon chronic dosing are possible, but unlikely to be developed. This article is part of a Special Issue entitled 'Cognitive Enhancers'. © 2012 Elsevier Ltd. All rights reserved.

Loading Charite Clinical Research Organisation collaborators
Loading Charite Clinical Research Organisation collaborators